58.85

5.11% 2.86

Pre-market: 58.45 -0.40 -0.68%

Crispr Therapeutics Ag (CRSP)

Overview News Price History Option Chain Financials Why CRSP Down? Discussions Forecast

Crispr Therapeutics Ag stock is traded at $58.85, with a volume of 2.56M. It is up +5.11% in the last 24 hours and up +4.33% over the past month. Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Previous Close:

$55.99

Open:

$55.99

24h Volume:

2.56M

Relative Volume:

1.02

Market Cap:

$5.61B

Revenue:

$170.10M

Net Income/Loss:

$-239.59M

P/E Ratio:

-21.02

EPS:

-2.8

Net Cash Flow:

$-191.20M

1W Performance:

+10.41%

1M Performance:

+4.33%

6M Performance:

+54.66%

1Y Performance:

+15.08%

1-Day Range:

$54.93

$59.77

1-Week Range:

$51.00

$59.77

52-Week Range:

$30.04

$78.48

Crispr Therapeutics Ag Stock (CRSP) Company Profile

Name

Crispr Therapeutics Ag

Sector

Healthcare (1131)

Industry

Biotechnology (632)

Phone

(617) 315-4600

Address

BAARERSTRASSE 14, ZUG

Employee

393

Twitter

@crisprtx

Next Earnings Date

2025-10-31

Latest SEC Filings

CRSP's Discussions on Twitter

Compare CRSP with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRSP Crispr Therapeutics Ag	58.85	5.34B	170.10M	-239.59M	-191.20M	-2.80
VRTX Vertex Pharmaceuticals Inc	457.26	117.50B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	722.83	76.06B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	464.56	62.53B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	916.31	56.75B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	205.04	44.10B	447.02M	-1.18B	-906.14M	-6.1812

Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-18-25	Initiated	JP Morgan	Overweight
Feb-14-25	Upgrade	Evercore ISI	In-line → Outperform
Feb-12-25	Upgrade	TD Cowen	Sell → Hold
Feb-03-25	Initiated	H.C. Wainwright	Buy
Aug-06-24	Reiterated	Needham	Buy
Aug-02-24	Initiated	Rodman & Renshaw	Buy
Jun-28-24	Resumed	Guggenheim	Neutral
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-11-23	Downgrade	TD Cowen	Market Perform → Underperform
Oct-17-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-27-23	Initiated	Mizuho	Buy
Aug-17-23	Upgrade	Citigroup	Neutral → Buy
May-30-23	Initiated	William Blair	Outperform
Apr-13-23	Initiated	Cantor Fitzgerald	Overweight
Mar-21-23	Initiated	Bernstein	Mkt Perform
Mar-17-23	Initiated	Bryan Garnier	Buy
Mar-07-23	Initiated	Robert W. Baird	Neutral
Oct-11-22	Initiated	Morgan Stanley	Underweight
Aug-09-22	Downgrade	Barclays	Overweight → Equal Weight
Jun-23-22	Downgrade	Evercore ISI	Outperform → In-line
Jun-17-22	Initiated	BMO Capital Markets	Outperform
Apr-28-22	Initiated	Credit Suisse	Neutral
Dec-07-21	Initiated	Cowen	Market Perform
Oct-19-21	Initiated	SVB Leerink	Outperform
Jun-14-21	Upgrade	Citigroup	Sell → Neutral
Apr-21-21	Upgrade	Jefferies	Hold → Buy
Mar-04-21	Initiated	JMP Securities	Mkt Outperform
Dec-10-20	Reiterated	Chardan Capital Markets	Buy
Dec-10-20	Downgrade	Jefferies	Buy → Hold
Dec-10-20	Reiterated	Needham	Buy
Dec-07-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Oct-23-20	Initiated	RBC Capital Mkts	Sector Perform
Oct-05-20	Initiated	BofA Securities	Buy
Jul-28-20	Reiterated	Needham	Buy
Jul-14-20	Initiated	SunTrust	Buy
Jun-15-20	Reiterated	Canaccord Genuity	Buy
Mar-05-20	Initiated	Stifel	Hold
Feb-03-20	Downgrade	Evercore ISI	Outperform → In-line
Nov-19-19	Upgrade	William Blair	Mkt Perform → Outperform
Nov-12-19	Upgrade	Oppenheimer	Perform → Outperform
Aug-01-19	Initiated	Jefferies	Buy
Jul-26-19	Initiated	Canaccord Genuity	Buy
Jun-10-19	Initiated	ROTH Capital	Buy
Apr-12-19	Initiated	Evercore ISI	Outperform
Mar-14-19	Initiated	William Blair	Mkt Perform
Jan-28-19	Downgrade	Goldman	Buy → Neutral
Jan-22-19	Downgrade	Citigroup	Neutral → Sell

View All

Crispr Therapeutics Ag Stock (CRSP) Latest News

Dec 04, 2025

Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown - MSN

Dec 04, 2025

Will CRISPR Therapeutics AG (1CG) stock return to pre crash levelsWeekly Trade Report & Weekly High Potential Stock Alerts - Newser

Dec 04, 2025

Is CRISPR Therapeutics AG stock a bargain at current levelsJuly 2025 Catalysts & Safe Capital Investment Plans - Newser

Dec 04, 2025

Cathie Wood’s Buys And Rumors Aside, Here’s Why Crispr Therapeutics Is A Strong Buy (CRSP) - Seeking Alpha

Dec 04, 2025

Rhumbline Advisers Buys New Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat

Dec 04, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Nasdaq Index Biotech Momentum - Kalkine Media

Dec 04, 2025

Dec 03, 2025

Bernstein Reaffirms Their Hold Rating on Crispr Therapeutics AG (CRSP) - The Globe and Mail

Dec 03, 2025

Will CRISPR Therapeutics AG stock continue upward momentumLayoff News & Weekly Top Stock Performers List - Newser

Dec 03, 2025

Can CRISPR Therapeutics AG (1CG) stock deliver double digit returnsMarket Volume Summary & Long Hold Capital Preservation Tips - Newser

Dec 03, 2025

How dovish Fed policy supports CRISPR Therapeutics AG (1CG) stockJuly 2025 EndofMonth & Fast Entry High Yield Stock Tips - Newser

Dec 03, 2025

Will CRISPR Therapeutics AG (1CG) stock outperform benchmarksMarket Sentiment Summary & High Conviction Buy Zone Picks - Newser

Dec 03, 2025

Will CRISPR Therapeutics AG (1CG) stock outperform value peers2025 Price Targets & High Accuracy Trade Alerts - Newser

Dec 03, 2025

Will CRISPR Therapeutics AG (1CG) stock hit analyst forecastsMarket Sentiment Summary & AI Based Trade Execution Alerts - Newser

Dec 03, 2025

Dec 02, 2025

CRISPR Therapeutics: CTX310 De-Risks, CASGEVY Disappoints Amid Takeover Rumors (CRSP) - Seeking Alpha

Dec 02, 2025

Dec 01, 2025

The Best CRISPR Companies for 2025 - The Motley Fool

Dec 01, 2025

Crispr Therapeutics (CRSP) Gains Amid Takeover Speculation - GuruFocus

Dec 01, 2025

Crispr Therapeutics pares loss amid takeover speculation (CRSP:NASDAQ) - Seeking Alpha

Dec 01, 2025

Inflation Data: Can SGBX stock maintain operating marginsMarket Performance Recap & Detailed Earnings Play Alerts - BỘ NỘI VỤ

Dec 01, 2025

Crispr Therapeutics (CRSP) Shares React to M&A Rumor - GuruFocus

Dec 01, 2025

Crispr Therapeutics rumor highlighted in Betaville blog - TipRanks

Dec 01, 2025

Loomis Sayles & Co. L P Has $41.68 Million Stock Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat

Dec 01, 2025

What CRISPR Therapeutics’ (CRSP) Latest Trial Results Mean for Investors - MSN

Dec 01, 2025

Nov 30, 2025

West Family Investments Inc. Takes Position in CRISPR Therapeutics AG $CRSP - MarketBeat

Nov 30, 2025